# Efficacy and Safety of Ascending Doses of Arpraziquantel in Children Infected With Opisthorchis Viverrini

> **NCT07262814** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Jennifer Keiser** · enrollment: 125 (estimated)

## Conditions studied

- Opisthorchis Viverrini

## Interventions

- **DRUG:** Apraziquantel

## Key facts

- **NCT ID:** NCT07262814
- **Lead sponsor:** Jennifer Keiser
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-15
- **Primary completion:** 2026-08
- **Final completion:** 2026-08
- **Target enrollment:** 125 (ESTIMATED)
- **Last updated:** 2026-03-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07262814

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07262814, "Efficacy and Safety of Ascending Doses of Arpraziquantel in Children Infected With Opisthorchis Viverrini". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT07262814. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*